Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Cardiomyopathy, Hypertrophic
Interventions: Mavacamten, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
Interventions: MRI Guided Transrectal Periuretheral Transitional Zone Ablation; Device
Lead sponsor: Prostate Laser Center, PLLC; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcopenia
Interventions: Peanut protein powder, Full body resistance training; Dietary Supplement · Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: Not listed
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 11
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 8 more

Conditions: Acne Scars - Mixed Atrophic and Hypertrophic
Interventions: Hybrid fractional laser, Alastin Regenerating Skin Nectar with TriHex Technology, Cetaphil face cream; Device · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions: Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines); Behavioral · Drug
Lead sponsor: Wayne State University; Other
Eligibility: 35 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Left Ventricular Hypertrophy
Interventions: Exercise training, women, marathon; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nonobstructive Hypertrophic Cardiomyopathy
Interventions: HTX-001; Drug
Lead sponsor: Haya Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Kansas City, Missouri • Cincinnati, Ohio

Conditions: Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions: Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Anemia, Fatigue, Fever, Lymphadenopathy, Lymphocytosis, Night Sweats, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma, Splenomegaly, Thrombocytopenia, Weight Loss
Interventions: Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study, Ritonavir, Quality-of-Life, Questionnaire; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Duarte, California

Conditions: Lumbar Spinal Stenosis, Cardiac Amyloidosis, ATTR Amyloidosis Wild Type, ATTR Gene Mutation, ATTRV122I Amyloidosis, Cardiomyopathy, Hypertrophic
Interventions: Tc99-PYP or Tc99-HDMP Scan; Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 50 Years and older
Enrollment: 1,663 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Beverly Hills, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Surgical Incision, Surgery--Complications, Surgical Wound, Surgical Site Infection, Scar, Hypertrophic Scar
Interventions: Topical zinc oxide vs. petrolatum post-surgical scars; Drug
Lead sponsor: Melissa Pugliano-Mauro; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Pittsburgh, PA, Pennsylvania

Conditions: Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Interventions: Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Naples, Florida • O'Fallon, Illinois • Springfield, Illinois + 5 more

Conditions: Scar, Keloid, Hypertrophic Scar, Cicatrix
Interventions: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer, Active Comparator Onion Skin Extract Gel (Mederma), Active Comparator Silicone Gel (Kelo-Cote), Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer; Other
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Hypertrophic Cardiomyopathy
Interventions: EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 21
States / cities: San Francisco, California • Stanford, California • Atlanta, Georgia + 16 more

Conditions: Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions: Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample; Radiation · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: High intensity exercise, Moderate intensity exercise; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertrophic Cardiomyopathy
Interventions: on-pump intracardiac echocardiography; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Splenomegaly
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder
Interventions: Nanatinostat in combination with valganciclovir; Drug
Lead sponsor: Viracta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 17
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more

Conditions: Muscle Composition, Sarcopenia, Hypertrophy, Inflammation
Interventions: Dietary Protein Intake; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 55 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: BPH, Erectile Dysfunction
Interventions: Alfuzosin 10 mg; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Non-obstructive Hypertrophic Cardiomyopathy
Interventions: mavacamten, Placebo; Drug
Lead sponsor: MyoKardia, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 32
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more

Conditions: Heart Failure, Reduced Ejection Fraction
Interventions: sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more

Search by objective public record fields.

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)

Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Young Adults

Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)

Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Zinc Oxide Versus Petrolatum Following Skin Surgery

Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Embryonal Tumor With Multilayered Rosettes

High Intensity Exercise for Increasing Fitness in Patients With Hypertrophic Cardiomyopathy

OPIE in the Thin Interventricular Septum

Spleen Size in Peripheral Blood Stem Cell Donors

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

Effects of Increased, Egg-Based Protein Intake on Muscle Composition,

Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.